Logo

Pfizer and OPKO’s Ngenla (somatrogon) Receives EC’s Marketing Authorization for the Treatment of Pediatric Growth Hormone Deficiency

Share this

Pfizer and OPKO’s Ngenla (somatrogon) Receives EC’s Marketing Authorization for the Treatment of Pediatric Growth Hormone Deficiency

Shots:

  • The marketing authorization was based on the P-III study to evaluate the safety & efficacy of Ngenla (qw) vs Genotropin (qd) in a ratio (1:1) in 224 prepubertal, treatment-naïve patients aged ≥3yrs. with GHD at ~20 countries
  • The study met its 1EPs of non-inferiority as measured by annual height velocity @12mos., was well tolerated & had a safety profile, 95% of patients switched into the open-label extension study & received the treatment, improved the mean overall life interference total score @12wks.
  • Ngenla is approved for pediatric GHD in Canada, Australia & Japan while the marketing authorization is valid in all EU Member States, Iceland, Norway & Liechtenstein

 Ref: Pfizer | Image: Pfizer

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions